ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME: CHOOSING THE BASIS MEDICATION

Российский кардиологический журнал

M. V. Lebedeva¹ 

[1] Кафедра терапии и профболезней ПМГМУ им. И.М. Сеченова;

关键词: arterial hypertension;    metabolic syndrome;    entodelin-1;    albuminuria;    quinapril;   

DOI  :  

来源: DOAJ

【 摘 要 】

The aim of the study was to assess the effectiveness of Accupro (Quinapril; 40 mg/d), as monotherapy and basis medication of combined therapy, in the treatment of arterial hypertension (AH) among patients with metabolic syndrome (MS). After 8 weeks of Accupro monotherapy (40 mg/d), target levels of blood pressure (BP) were achieved in 68% of the patients. BP normalization correlated with endothelial function improvement. Accupro therapy (40 mg/d) was also well tolerated. Accupro (40 mg/d) could be recommended as an effective and safe basis medication for combined antihypertensive therapy in patients with AH and MS.

【 授权许可】

Unknown